In December 2024, IQVIA released a new white paper, developed in collaboration with GSK and GCOA, examining the significant economic and clinical burden of Respiratory Syncytial Virus (RSV) in older adults (age ≥60 years) across select high-income APEC countries, including China, Japan, South Korea, Canada, Singapore, New Zealand, Australia, Hong Kong, and Taiwan. The study…

This new GCOA paper, launched ahead of Silver Economy Forum 2024, examines how industry leaders are creating business value, engaging their workforce, improving productivity and economic value, and advancing top private-sector priorities by taking action on preventive health for their employees through employee benefits and policies, such as supporting access to adult immunization, mental health…

Respiratory infections like influenza, RSV (respiratory syncytial virus), and now COVID-19, among others, place a substantial and growing burden on health systems. Among these three infections—responsible for the so called “tripledemic”—RSV is the least recognized. There is low awareness of RSV among healthcare professionals and the general public and little understanding of the disease burden…

The IQVIA Institute for Human Data Science released a new report at the 2023 Silver Economy Forum, Trends in Global Adult Vaccination: A View from Five Global Cities. The report, which was created in collaboration with GCOA and funded by GSK, explores the role of social and structural determinants of health in adult vaccine access…

A July 2023 report from GSK, in collaboration with the IQVIA Institute for Human Data Science and the Global Coalition on Aging (GCOA) examined the impact of the COVID pandemic on the uptake of adult vaccination around the world. The report estimated approximately 100 million fewer doses of some adult vaccines (excluding Covid-19 vaccines) were…